Right Anterior Insula: Core Region of Hallucinations in Cognitive Neurodegenerative Diseases by Blanc, Frédéric et al.
HAL Id: hal-02288100
https://hal-imt-atlantique.archives-ouvertes.fr/hal-02288100
Submitted on 13 Sep 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Right Anterior Insula: Core Region of Hallucinations in
Cognitive Neurodegenerative Diseases
Frédéric Blanc, Vincent Noblet, Nathalie Philippi, Benjamin Cretin, Jack
Foucher, Jean-Paul Armspach, François Rousseau
To cite this version:
Frédéric Blanc, Vincent Noblet, Nathalie Philippi, Benjamin Cretin, Jack Foucher, et al.. Right
Anterior Insula: Core Region of Hallucinations in Cognitive Neurodegenerative Diseases. PLoS ONE,
Public Library of Science, 2014, 9 (12), pp.e114774. ￿10.1371/journal.pone.0114774￿. ￿hal-02288100￿
RESEARCH ARTICLE
Right Anterior Insula: Core Region of
Hallucinations in Cognitive
Neurodegenerative Diseases
Fre´de´ric Blanc1,2,3,4*, Vincent Noblet2, Nathalie Philippi1,2,3, Benjamin Cretin1,2,3,
Jack Foucher2, Jean-Paul Armspach2, Franc¸ois Rousseau2, the Alzheimer’s
Disease Neuroimaging Initiative
1. University Hospital of Strasbourg, Neuropsychology Unit, Neurology Service, Strasbourg, France, 2.
University of Strasbourg and CNRS, ICube laboratory UMR 7357, FMTS (Fe´de´ration de Me´decine
Translationnelle de Strasbourg), Strasbourg, France, 3. University Hospital of Strasbourg, CMRR (Memory
Resources and Research Centre), Strasbourg, France, 4. University Hospital of Strasbourg, Day Hospital of
Geriatrics, Geriatrics Service, Strasbourg, France
*Frederic.Blanc@chru-Strasbourg.fr
Abstract
Objectives:We investigated the neural basis of hallucinations Alzheimer’s disease
(AD) by applying voxel-based morphometry (VBM) to anatomical and functional
data from the AD Neuroimaging Initiative.
Methods: AD patients with hallucinations, based on the Neuropsychiatric Inventory
(NPI-Q) (AD-hallu group; n539), were compared to AD patients without
hallucinations matched for age, sex, educational level, handedness and MMSE
(AD-c group; n539). Focal brain volume on MRI was analyzed and compared
between the two groups according to the VBM method. We also performed voxel-
level correlations between brain volume and hallucinations intensity. A similar
paradigm was used for the PET analysis. ‘‘Core regions’’ (i.e. regions identified in
both MRI and PET analyses, simply done by retaining the clusters obtained from
the two analyses that are overlapping) were then determined.
Results: Regions with relative atrophy in association with hallucinations were:
anterior part of the right insula, left superior frontal gyrus and lingual gyri. Regions
with relative hypometabolism in association with hallucinations were a large right
ventral and dorsolateral prefrontal area. "Core region" in association with
hallucinations was the right anterior part of the insula. Correlations between
intensity of hallucinations and brain volume were found in the right anterior insula,
precentral gyrus, superior temporal gyrus, and left precuneus. Correlations
between intensity of hallucinations and brain hypometabolism were found in the left
midcingulate gyrus. We checked the neuropathological status and we found that
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the 4 patients autopsied in the AD-hallu group had the mixed pathology AD and
Dementia with Lewy bodies (DLB).
Conclusion: Neural basis of hallucinations in cognitive neurodegenerative
diseases (AD or AD and DLB) include a right predominant anterior-posterior
network, and the anterior insula as the core region. This study is coherent with the
top-down/bottom-up hypotheses on hallucinations but also hypotheses of the key
involvement of the anterior insula in hallucinations in cognitive neurodegenerative
diseases.
Introduction
The reported prevalence of hallucinations in Alzheimer’s disease (AD) patients
varies from 0 to 25% depending on the study [1]. However, if one considers only
studies that included neuropathologic diagnosis, the values range from 15 to 20%
[2]. Hallucinations are consistently reported to be more frequent in Dementia
with Lewy bodies (DLB) than in AD, with a prevalence of 75% in DLB [2, 3].
In previous studies of AD patients, hallucinations were related to posterior
region changes, with a relative occipital atrophy [4], more occipital white matter
hyperintensities [5], and enlarged ventricles [6, 7]. The brain structures
responsible for such behavioral modifications have been more extensively
explored in DLB, where hallucinations were found to be correlated to posterior
decreased perfusion including left posterior cingulate and precuneus [8], but also
angular gyri, right supramarginal gyrus and 4th occipital gyrus [9]. Moreover,
Taylor et al started hallucinations in DLB patients in one third of the cases using
transcranial magnetic stimulation of the occipital lobe [10]. They found also that
the severity of visual hallucinations were strongly correlated with occipital lobe
excitability [10]. DLB patients with hallucinations were shown to have greater
gray matter (GM) loss in the right inferior part of the frontal lobe [11]. PD
patients with hallucinations compared to Parkinson’s disease (PD) patients
without, matched for cognitive status, exhibited grey matter atrophy in the
cuneus, lingual and fusiform gyri, middle occipital lobe, inferior parietal lobule,
and cingulate, paracentral and precentral gyri [12].
The mechanisms of visual hallucinations in cognitive neurodegenerative
diseases such as AD, DLB, or PD are debated with numerous different hypotheses
[13]. First the release phenomenon is a mechanism of disinhibition of neurons
with spontaneous activity of them: particularly cholinergic denervation of
occipital associative areas would induce hallucinations [14]. Against this
hypothesis O’Brien et al have found an elevation of nicotinic receptor binding in
such areas in DLB patients with hallucinations [15]. Visual disturbances or
disturbances in visuo-cortical areas are also frequently supposed to be a core
mechanism of hallucinations: many studies support this bottom-up visual
processing hypotheses, with impaired visual processing and reduced activation in
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visual cortices [16, 17]. More recently, Diederich et al., suggested that visual
hallucinations should be considered as a dysregulation of the gating and filtering
of external perception and internal image production [18]. Collerton et al.,
developed the "Perception and Attention deficit Model": a combination of
impaired attentional binding (top-down) and perceptual processes (bottom-up)
[16]. Finally Shine et al., have proposed, but only for PD, the hypotheses that the
difficulties to activate the dorsal attention network at the presentation of a visual
stimulus, is responsible for a conflict resolution processed by neural networks
unprepared to do it (default mode network and ventral attention network also
named salience network), and thus hallucinations [19].
A better knowledge of the mechanisms of neuropsychiatric symptoms in AD,
especially regarding hallucinations, is of importance since currently used
antipsychotic treatments carry an increased long-term risk of mortality [20].
The aim of this study was to investigate the neural correlates of hallucinations
in AD patients from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). We
used a dual approach based (1) on the analysis of focal volume on AD brain MRI
using voxel-based morphometry (VBM) to localize relative brain atrophy
associated with the presence and intensity of hallucinations, and (2) on the
analysis of functional data with fluorodesoxyglucose positron emission tomo-
graphy (FDG-PET), using SPM to evaluate voxelwise brain metabolism
modifications associated with the presence and intensity of hallucinations. We
hypothesised that in AD patients with hallucinations, we would find more
posterior (occipital) and anterior (frontal) atrophy and hypometabolism.
Method
Ethic
These data were analyzed anonymously. All subjects gave written, informed
consent prior to participation through the local institutional review boards at
participating institutions. For the purpose of this study we used the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) data that were previously collected
across 50 sites. Study subjects gave written informed consent at the time of
enrolment for data collection and completed questionnaires approved by each
participating site’s Institutional Review Board (IRB). The complete list of ADNI
sites’ IRBs can be found in the link: http://adni.loni.ucla.edu/about/data-statistics/
. Specifically, they are: Albany Medical College, Banner Alzheimer’s Institute,
Baylor College of Medicine, Boston University, Brigham and Women’s Hospital,
Butler Hospital Memory & Aging Program, Case Western Reserve University,
Cleveland Clinic, Columbia University, Darthmouth – Hitchcock Medical Center,
Dent Neurologic Institute, Duke University Medical Center, Emory University,
Georgetown University, Howard University, Indiana University, Jefferson
Hospital for Neuroscience, Johns Hopkins University, Mayo Clinic, Jacksonville,
Mayo Clinic, Rochester, McGill University/Jewish General Hospital Memory
Clinic, Medical University of South Carolina, Mount Sinai School of Medicine,
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Neurological Care of Central New York, New York University Medical Center,
Northwestern University, Ohio State University, Olin Neuropsychiatry Research
Center, Oregon Health and Science University, Parkwood Hospital, Premiere
Research Institute, Rhode Island Hospital, Rush University Medical Center, Saint
Joseph’s Health Center, London, Ontario, Stanford University, Banner Sun Health
Research Institute, Sunnybrook Health Sciences, University of Alabama,
Birmingham, University of British Columbia, University of California, Davis,
University of California, Irvine, University of California, Irvine-BIC, University of
California, Los Angeles, University of California, San Diego, University of
California, San Francisco, University of Kansas, University of Kentucky,
University of Michigan, Ann Arbor, University of Nevada School of Medicine, Las
Vegas, University of Pennsylvania, University of Pittsburgh, University of
Rochester, University of Southern California, University of Texas Southwestern
Medical Center, University of Wisconsin, Wake Forest University, Washington
University St. Louis, Wein Center for Clinical Research and Yale University
School of Medicine. The protocol was submitted to appropriate Boards and their
written unconditional approval obtained and submitted to Regulatory Affairs at
the Alzheimer’s Disease Neuroimaging Initiative Coordinating Center (ADNI-
CC) prior to commencement of the study.
Subjects from the Alzheimer’s Disease Neuroimaging Initiative
Database
Data used in the preparation of this article were obtained from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu). The ADNI
was launched in 2003 by the National Institute on Aging (NIA), the National
Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug
Administration (FDA), private pharmaceutical companies and non-profit
organizations, as a $60 million, 5-year public-private partnership. The primary
goal of ADNI has been to test whether serial magnetic resonance imaging (MRI),
positron emission tomography (PET), other biological markers, and clinical and
neuropsychological assessment can be combined to measure the progression of
mild cognitive impairment (MCI) and early Alzheimer’s disease (AD).
Determination of sensitive and specific markers of very early AD progression is
intended to aid researchers and clinicians to develop new treatments and monitor
their effectiveness, as well as lessen the time and cost of clinical trials.
The Principal Investigator of this initiative is Michael W. Weiner, MD, VA
Medical Center and University of California – San Francisco. For up-to-date
information, see www.adni-info.org.
ADNI is a large multicenter, longitudinal, observational trial taking place across
the United States and Canada, launched in 2003, in which subjects with normal
cognition, amnestic mild cognitive impairment (MCI), and mild AD are followed
up with periodic neuropsychological testing, multiple imaging techniques, and
fluid biomarkers. Subjects with complete baseline clinical datasets (n5765;
including 387 amnestic MCI, 200 controls and 178 mild AD) were included in the
Hallucinations in Cognitive Neurodegenerative Diseases: Neural Basis
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current study. They had a study partner able to provide an independent
evaluation of the patient. They also had a modified Hachinski Ischemic Score #4
and a Geriatric Depression Scale (GDS, short form) ,6. Subjects did not have
other significant neurological disease, significant active psychiatric disorders, or
alcohol or substance abuse within 2 years of screening. For full inclusion/exclusion
criteria see http://www.adni-info.org.
AD subjects fulfilled these criteria: CDR score of 1.0 or 2.0 and met the
National Institute of Neurologic and Communicative Disorders and Stroke and
the Alzheimer’s Disease and Related Disorders Association Work Group criteria
(NINCDS/ADRDA criteria) for probable AD [21]. The patients fulfilled also the
Dubois’ research criteria for AD – the high specificity of which has been
confirmed - [22], because all of them had memory impairment, atrophy of
hippocampus on brain MRI, and abnormal CSF for all the subjects that
underwent lumbar puncture (see table 1) [23].
In the ADNI cohort, evaluation of hallucinations was based on the brief clinical
form of the Neuropsychiatric Inventory (NPI) [24]. The brief clinical form of the
NPI, also called NPI-Q, is a retrospective (previous month) study-partner-
administered questionnaire covering 12 neuropsychiatric symptom domains:
delusions, hallucinations, agitation/aggression, dysphoria/depression, anxiety,
euphoria/elation, apathy/indifference, disinhibition, irritability/lability, aberrant
motor behaviors, nighttime behavioral disturbances, and appetite/eating dis-
turbances. The scripted NPI questionnaire includes a written screening question
for each domain. For hallucinations, the wording of the screening question is:
‘‘Does he/she have hallucinations, or false visions, or voices? Does he/she seem to
hear or see things that are not present?’’ (see https://www.alz.washington.edu/
npiq/). Neuropsychiatric manifestations within a domain are rated by the study
partner in terms of severity/intensity on a three point scale: 1: mild (noticeable but
not significant change), 2: moderate (significant but not a dramatic change), 3:
severe (very marked or prominent; a dramatic change).
Among the 565 patients, AD patients with hallucinations (AD-hallu group)
were compared to AD patients without hallucinations (AD-c group) matched for
age, sex, educational level, handedness and MMSE (Table 1). Forty-nine AD
patients were found to have hallucinations according to the NPI-Q. However,
only 39 patients were included because the 6 other patients did not have brain
MRI and/or FDG-PET at the same time as the NPI-Q, and 4 patients were
diagnosed as AD-MCI. The comparison of AD-hallu and AD-c for the
neuropsychiatric symptom domains of the NPI-Q logically showed a clear
difference for the item ‘hallucinations’ (x2578.000, P,.0001), a difference for the
domains ‘agitation/aggression’ (x254.255, P5.039), ‘anxiety’(x257.429, P5.006),
and ‘aberrant motor behaviors’ (x255.769, P5.016), but no difference for the
other domains. There were no significant differences between the AD-hallu group
and the AD-c group in terms of psychotropic treatment (antidepressant,
benzodiazepine and antipsychotic drugs), or AD treatment (cholinesterase
inhibitors and memantine). Finally 39 healthy elderly controls matched for age,
gender, educational level and handedness were also considered.
Hallucinations in Cognitive Neurodegenerative Diseases: Neural Basis
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Brain FDG-PET and MRI images were downloaded from the ADNI LONI
website in NIFTI format.
MRI Acquisition
Standard 1.5T T1-weighted images obtained using volumetric 3D MPRAGE
protocol with resolutions ranging from 0.9 mm60.9 mm61.20 mm to
1.3 mm61.3 mm61.20 mm were included from the ADNI database. For
detailed information on the MRI protocols and preprocessing steps, see Jack et al
[25]. It is of importance to notice that a major effort was devoted in establishing
the MRI protocol specifications to standardize 3D T1-weighted sequences across
sites and platforms in order to enable the scientific community to carry out
relevant multicentric morphometric study (see [25] for details). In our work, we
choose to restrict our analysis to 1.5 MRI scans only (3T MRI examination were
discarded) in order to have even more consistent data.
FDG-PET Acquisition
Subjects were scanned after a 4-hour fast (water only). Plasma glucose had to be
#180 mg/dl for FDG to be injected. An intravenous catheter was placed in one
arm for injection of 18F-FDG. Imaging began at 30 minutes post-injection, and
the scan was acquired as six 5-minute frames. For detailed information on the
MRI protocols and preprocessing steps, see Langbaum et al., [26].
Image Analysis
MRI image analysis
For MRI analysis, 39 patients with hallucinations (AD-hallu group) were
compared to 39 control patients (AD-c group). Each of these two groups was
preliminary compared to the group of 39 healthy elderly controls (HC). Focal
brain atrophy of gray mater (GM) and white matter (WM) was compared
between groups using the VBM (voxel-based morphometry) method provided in
SPM12b (Statistical Parametric Mapping, Wellcome Department of Cognitive
Neurology, London, U.K.) and ran under Matlab R2010a software (The
MathWorks, Natick, MA). We also performed voxel-level correlations between
GM/WM atrophy and hallucinations intensity.
Voxel-based morphometry analyses included image pre-processing and
statistical analyses. Anatomical MRI images were spatially pre-processed using
standard procedures [27]. All T1 structural images were first segmented, bias
corrected and spatially normalized to the Montreal Neurological Institute (MNI)
space using an extension of the unified segmentation procedure [28] that includes
six classes of tissue. Spatial normalization is then refined using DARTEL
algorithm [29] and a customized brain template is built from the set of all images.
The VBM analysis was done on modulated gray matter and white matter
images (i.e., GM and WM segmentation maps were multiplied by the Jacobian of
the transformation in order to account for the variation of volume induced by the
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transformation). These images were smoothed with a Gaussian kernel (FWHM:
8 mm).
Then, we performed voxel-level comparison of GM (resp. WM) atrophy on the
one hand between each of the AD groups (AD-hallu and AD-c) and the HC-group
and on the other hand between the AD-hallu group and the AD-c group using a
two-sample t-test while considering age and total amount of GM (resp. WM) as
covariates. Statistical maps were thresholded either with PFWE,0.05 corrected for
familywise error (for the comparisons between AD groups and HC-group) or
P,0.001 without p-value correction (for the comparison between AD-hallu and
AD-c) and with a minimum cluster size of 25 voxels. Additionally, we performed
voxel-level correlations between GM (resp. WM) atrophy and the intensity of
hallucinations (NPI-Q) for the AD-hallu group using the intensity of
hallucinations as covariate of interest and age and total amount of GM (resp.
WM) as confounders. Corresponding statistical maps were also thresholded with
P,0.001 (uncorrected p-value) and with a minimum cluster size of 25 voxels
(200 mm3).
PET image analysis
For FDG-PET analysis, 19 patients with hallucinations (AD-hallu subgroup) were
compared to 20 control patients (AD-c subgroup). Each group was also compared
to 20 healthy elderly controls (HC subgroup)
Focal brain metabolism was compared between groups and voxel-level
correlations between brain metabolism and hallucinations intensity were
performed within AD-hallu group. To this end, all PET images were spatially
normalized to the Montreal Neurological Institute (MNI) space. This was done by
first registering each PET image on the corresponding MRI image for each subject
using an affine transformation. Then, the transformations estimated from MRI
analysis using Dartel algorithm were then applied on the affinely registered PET
images. By this way, we benefit from the structural information of MRI data to
accurately match all PET images. These normalized images were then smoothed
with a Gaussian kernel (FWHM: 8 mm).
We performed voxel-level comparisons of brain metabolism between either the
AD-hallu group or the AD-c group with the HC group, and between the AD-hallu
group and the AD-c group using a two-sample t-test while considering age and
mean brain metabolism as nuisance variables. Statistical maps were thresholded
with P,0.001 (uncorrected p-value) and with a minimum cluster size of 25
voxels. Additionally, we performed voxel-level correlations between focal brain
metabolism and the intensity of hallucinations (NPI-Q) for the AD-hallu group
using a one-sample t-test with the intensity of hallucinations as the covariate of
interest and age and mean brain metabolism as confounders. Corresponding
statistical maps were also thresholded with P,0.001 (uncorrected p-value) and
with a minimum cluster size of 25 voxels.
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MRI and PET image analysis: ‘‘core regions’’
We define as "core regions" the regions that were identified in both MRI and PET
analyses. This is simply done by retaining the clusters obtained from the two
analyses that are overlapping. We looked for these "core regions" either for the
comparison between AD-hallu and AD-cor for the correlation analyses with the
intensity of hallucinations.
MNI Space Utility (MSU, http://www.ihb.spb.ru/,pet_lab/MSU/MSUMain.
html), xjView software (http://www.alivelearn.net/xjview8/) and Talairach soft-
ware (http://www.talairach.org/index.html ) were used to create reports about
cluster localization in terms of Talairach Daemon anatomical region labels for
both MRI and PET analysis.
Neuropathological status
Based on the article of Toledo et al., [30] we checked the neuropathological status
of the patients included in this article to better understand the origin of
hallucinations in patients.
Statistical analysis
The Statistical Package for Social Sciences software (SPSS ver. 21.0.0.0, http://
www-01.ibm.com/software/analytics/spss/) was used for further statistical eva-
luation as required. Where appropriate, differences in demographic and clinical
data were assessed using parametric (ANOVA, t-tests) and non-parametric tests
(Kruskall-Wallis H, Mann-Whitney U). Post-hoc analysis were applied: Tukey
post-hoc test for ANOVA and Kruskall-Wallis post-hoc test for H. For categorical
measures, x2 tests were applied. For each test statistic, a probability value of
P,0.05 was regarded as significant.
Results
Comparison of AD patients and healthy controls
Comparison with FWE correction (P,0.05) of GM of AD-hallu patients with
healthy controls showed significant relative atrophy in hippocampi and amygdalas
(Figure 1A left). The same regions were found for the comparison of AD-c
patients and healthy controls (Figure 1A right). The whole cluster size of voxels is
of 5554 when comparing AD-c to healthy controls, and of 1389 when comparing
AD-hallu to healthy controls.
Comparison with FWE correction (P,0.05) of WM of AD-hallu patients with
healthy controls showed significant relative atrophy in WM at the vicinity of the
anterior part of left hippocampus and amygdalae and fornix (data not shown).
The same regions were found for the comparison of AD-c patients and healthy
controls but bilaterally.
Without P-value correction (P,0.001), the comparison of GM and WM of
AD-hallu patients with healthy controls showed significant relative atrophy in the
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Figure 1. Brain regions of relative atrophy of AD patients with hallucinations compared to healthy
controls (A and B left) and AD patients without hallucinations compared to healthy controls (A and B
right). Brain regions of relative hypometabolism of AD patients compared to healthy controls (C). (A: for gray
matter only: T5p,0.05, correction FWE, minimum cluster size525 voxels; B: T5p,0.001, without correction,
minimum cluster size525 voxels; C. T5p,0.001, without correction, minimum cluster size525 voxels) A. The
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whole hippocampi and input and output pathways of the hippocampi including
amygdalas, entorhinal cortices, fornix, thalami and cingulate gyri (Figure 1B left).
The same regions were found for the comparison of AD-c patients and healthy
controls (Figure 1B right).
Comparison with FWE correction (p,0.05) of FDG-PET of AD-hallu patients
with healthy controls did not show any relative hypotemabolism, nor
hypermetabolism. Comparison with FWE correction (p,0.05) of FDG-PET of
AD-c patients with healthy controls showed little hypometabolism of the right
precuneus (number of voxels 54, T55.80, x59, y5260, z531.5). Comparison
without correction (p,0.001) showed hypometabolism of the temporal, parietal
and frontal lobes (figure 1C).
AD brain focal atrophy and hallucinations
The main brain regions that showed significant relative atrophy in association
with hallucinations in AD patients (AD-hallu minus AD-c) were in WM the
lingual gyri of the occipital lobe (right more than left), (Table 2), and in GM: the
anterior part of the right insular cortex and a discrete part of the left superior
frontal gyrus (Table 2 and Figure 2).
AD brain focal atrophy and intensity of hallucinations
One correlation was found between hallucination intensity (NPI-Q, score 1 to 3)
and regional WM volume in the AD-hallu group: the left precuneus (Table 2B).
Correlations were found between hallucination level and regional GM volume
in some brain regions: Right anterior part of the insula, right precentral gyrus, and
right superior temporal gyrus (Table 2B).
AD brain metabolism and hallucinations
The comparison of brain metabolism between the two groups showed that
hallucinations were associated with extensive hypometabolism in the right frontal
lobe (anterior part including the orbito-frontal region and insula; Figure 3 and
Table 3). This comparison also highlighted patchy hypermetabolism in the left
hemisphere including superior frontal gyrus, fusiform gyrus, post-central gyrus,
and the supramarginal gyrus and precuneus in the AD-hallu group (Table 3).
relative atrophy involves hippocampi and amygdalas for the two AD groups, for the analysis with correction. B.
The relative atrophy of gray matter (red) and white matter (yellow) involves also input and output pathways of
the hippocampi including amygdalas, entorhinal cortex, fornix, thalami and cingulate gyrus. C: Relative
hypometabolism (FDG PET) of AD-hallu (left) and AD-c (right) compared to healthy controls. Right is right.
doi:10.1371/journal.pone.0114774.g001
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AD brain metabolism and intensity of hallucinations
Correlations between brain metabolism and intensity of hallucinations revealed a
hypometabolism in the left limbic lobe, cingulate gyrus (T54.34, number of
voxels5100; BA 24 figure 4), and in the right pre -central gyrus (T54.160,
number of voxels531).
Table 2. A. Brain Regions that Show Significant Relative Atrophy in Relation to the Presence of Hallucinations in AD patients.
Coordinates (mm, MNI)
Brain regions BA vicinity Side No. Voxels T value x y z p
A Insula, anterior part and inferior
frontal gyrus (GM)
13/45/47 R 594 4.13 45 28 6 0.000047
Frontal lobe, superior frontal gyrus
(GM)
6 L 70 3.72 29 27 61 0.00019
Occipital lobe, lingual gyrus (WM) 18 R/L 113 3.62 7.5 286 24 0.00026
B Frontal lobe, precentral gyrus (GM) 6 R 86 4.52 37 28 32 0.0000034
Insula, anterior part (GM) 13 R 75 3.77 34 10 14 0.00003
Temporal lobe, superior temporal
gyrus (GM)
21 R 69 4.02 51 26 213 0.00010
Parietal lobe, precuneus (WM) 7 L 63 4.37 214 257 71 0.0000053
T5p,0.001, uncorrected, minimum cluster size525 voxels; BA5Brodmann’s area; L5left; GM5gray matter; No.5number; R5right; sup. 5superior;
WM5white matter.
AD patients with hallucinations have been compared to matched (age, sex, handedness, educational level and MMSE) AD patients without hallucinations.
B. Correlation between Hallucination Intensity (NPI-Q) and Regional Brain Volume (MRI). Underlined brain regions are ‘‘core regions’’ of hallucinations
in AD (see Methods).
doi:10.1371/journal.pone.0114774.t002
Figure 2. Brain Regions of Relative Grey Matter Atrophy Associated with the Existence of
Hallucinations in AD Patients. Relative atrophy of GM (red): right anterior part of insula and inferior frontal
gyrus. (T5p,0.001, uncorrected, minimum cluster size525 voxels).
doi:10.1371/journal.pone.0114774.g002
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Core regions associated with hallucinations in AD
The common overlapping regions of focal changes in AD brain volume and
metabolism and hallucinations were the right anterior insula and inferior frontal
gyrus (Table 2 and figure 3).
We did not find any overlapping regions in which changes in AD brain volume
and metabolism were correlated with intensity of hallucinations.
Neuropathological results
Among the 39 AD-hallu patients, 4 were autopsied (patients 565, 691, 723, 834),
and among the AD-c patients 2 were autopsied (patients 53 and 400). The
neuropathological diagnosis for the 4 AD-hallu patients was AD and DLB for 3
and AD, DLB and medial temporal lobe pathology TDP 43 proteinopathy for 1.
The neuropathological diagnosis for the 2 AD-c patients was AD for one and AD,
DLB and medial temporal lobe pathology TDP 43 proteinopathy for 1.
Comparison of brain MRI of the 4 AD-hallu patients with AD and DLB to the
controls (P ,0.001, uncorrected, minimum cluster size of 25) showed atrophy of
right parahippocampal (BA35), superior temporal gyrus (BA38), left insula, right
Figure 3. Brain Regions with Relative Hypometabolism (red) and Relative Gray Matter Atrophy (yellow)
in Relation with Hallucinations. Relative hypometabolism of right inferior frontal gyrus, middle frontal gyrus
(including orbital part), and insula (anterior part) (slices z528 to 28). Core regions correspond to the common
part of relative hypometabolism and atrophy, including right inferior frontal gyrus and a part of right anterior
insula. (For MRI and FDG PET, p,0.001, uncorrected, minimum cluster size525 voxels). Right is right.
doi:10.1371/journal.pone.0114774.g003
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and left hippocampi, right and left thalami, right anterior cingulate (BA32), and
left supramarginal gyrus of the parietal lobe (BA3).
Comparison of brain PET of the 2 AD-hallu patients with AD and DLB to the
controls shows hypometabolism (P,0.001, uncorrected, minimum cluster size of
25) of right inferior and posterior temporal gyrus (BA 37 and 21), right cuneus of
occipital lobe, right precuneus of parietal lobe, right and left gyri of parietal lobes,
right and left middle frontal gyri.
Table 3. Brain Regions of Relative Hypometabolism Associated with the Existence of Hallucinations (Hypo), and Brain Regions of Relative
Hypermetabolism Associated with the Existence of Hallucinations (Hyper).
Coordinates MNI
(mm)
Brain Regions BA Vicinity Side No. Voxels T value x y z p
Hypo Frontal lobe, inferior, middle
frontal gyrus (orbital), and
insula (ant)
45/47/44/10/9 R 3625 4.56 46 25 2 0.000031
Hyper Frontal lobe, superior frontal gyrus 6 L 347 4.52 224 211 69 0.000036
Temporal lobe, fusiform gyrus 37 L 91 3.92 27 241 220 0.00020
Parietal lobe, postcentral gyrus
and precuneus
7 L L 90 3.79 215 253 74 0.00029
Parietal lobe, postcentral and
supramarginal gyri
40 353 3.71 251 221 33 0.00037
T5p,0.001, uncorrected, minimum cluster size525 voxels; ant5anterior; BA5Brodmann’s area; L5left; R5right; NA5not applicable; No.5number.
Underlined brain regions are ‘‘core regions’’ of hallucinations in AD (see Methods).
doi:10.1371/journal.pone.0114774.t003
Figure 4. Alzheimer’s Disease Brain Hypometabolism and Intensity of Hallucinations. Correlations
between brain hypometabolism and intensity of hallucinations in the left midcingulate gyrus (BA 24) (and
discretely right precentral gyrus, BA6). (T5p,0.001, uncorrected, minimum cluster size525 voxels). Right is
right.
doi:10.1371/journal.pone.0114774.g004
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Discussion
The aim of our study was to examine the possible structural and functional neural
correlates of hallucinations by contrasting AD hallucinators (AD-hallu) and AD
non hallucinators (AD-c). Even though AD-hallu and AD-c were matched for
cognitive and functional levels (MMSE, CDR and FAQ), AD-hallu had more
extensive brain atrophy and more extensive brain hypometabolism than AD-c.
Thus, a wide neuronal network seems to be implicated in the occurrence of
hallucinations in AD. We found three groups of regions. The first consisted of
‘‘core regions’’, with both structural and functional changes, including the right
anterior part of the insula and the inferior frontal gyrus next to. The second
consisted of regions that were associated with structural changes only: left
superior frontal gyrus and lingual gyri, and for intensity, right precentral gyrus,
right superior temporal gyrus, and left precuneus. The third consisted of regions
with hypoactivity only, comprising a large right ventral and dorsolateral
prefrontal area including orbito-frontal regions, and the left midcingulate gyrus
for intensity.
The core region underlying hallucinations in patients corresponds to the
anterior part of the right insula. The dysfunction of this region could involve
different mechanisms leading to hallucinations: (i) false attribution of a source to
a stimulus, (ii) a deficient intuitive judgment and (iii) a disruptive processing
across attentional networks .
(i) The insular cortex has many connections to the cortex and limbic system.
The insula integrates sensory input from the external world and from the internal
milieu [31]. The anterior insula – the agranular part of the insula – is known to be
extensively connected to limbic areas, higher order visual areas (including lingual
gyrus), and olfactory areas [31, 32]. The anterior insular cortex is of high
importance for self-awareness and the evaluation of emotional stimuli from others
[33, 34]. Thus, dysfunction of the anterior insula would disrupt these two
processes, particularly the discrimination between self-generated and external
information, and could therefore contribute to hallucinations, as has been
suggested in schizophrenia [32]. Goetz et al., have recently suggested that the
dysfunction of insula could lead to self-referential visual perceptions, and thus
hallucinations [34, 35]
(ii) The anterior insular has certain specific neurons, namely the Von Economo
neurons (VENs). These VENs are located in layer 5 of the cingulate gyrus and
anterior insular cortex, with a predominance in the right hemisphere [36]. These
regions are supposed to be involved in the fast intuitive assessment of complex
situations [36]. In situations with a high degree of uncertainty, we do not always
have sufficient time to perform deliberative cost-benefit analyses; we need rapid
intuitive judgments. In such situations, the cingulate gyrus and anterior insula are
active. Allman et al. have suggested that VENs – because of their larger size
compared to pyramid neurons – have rapidly conducting axons that may relay a
fast intuitive assessment of complex social situations, and so facilitate rapid
execution of decisions [36]. Dysfunction of regions of VENs (right predominant
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anterior insula) – core regions of hallucinations here –could be responsible for
non intuitive assessment of external information, including visual information,
and could facilitate hallucinations.
(iii) The anterior part of the insula is also involved in high-level cognitive
control and attentional processes. The anterior insula is a key region of the
"salience network" that permit to segregate the most relevant among internal and
external stimuli in order to guide behavior [37]. Anterior insula would permit to
switch between networks to facilitate access to attention and working memory
resources when a salient event is detected [37]. Thus in PD, patients with PD and
high misperceptions and more hallucinations displayed decreased resting state
functional connectivity between hubs of the ventral and dorsal attention networks
[38].
Among the anterior regions of the network identified in our study, the third
group of regions included a large right ventral prefrontal area including the
orbito-frontal region, as well as the anterior insula (Figure 3). Along with the
insula, the orbito-frontal cortex is known to be of importance for emotion,
particularly for negative emotion processing [39]. DLB patients and PD patients
with hallucinations have greater GM loss in the right inferior part of the frontal
lobe [11]. Moreover, this region was previously found to be correlated to
delusional states in AD, particularly the right inferior frontal gyrus [40].
The posterior part of the network of hallucinations in AD includes the lingual
gyri and left precuneus. Interestingly, these posterior regions were found after the
analysis of the WM but not the GM. The involvement of WM in the posterior part
of the brain could be the reflect of a local or more global deconnection of the
visual network. The lingual gyri are known to be of importance to process colors,
object forms, and complex visual scene [41]. Moreover, they are of importance for
the perceptual quality of self-luminosity or glow. At night or during poor
lightning, all visible objects appear to glow. And in patients with dementia, low
illumination is responsible for a higher rate of visual hallucinations [42]. Such
dysfunction of lingual gyri is probably a key point for visual hallucinations or
illusions.
Of importance concerning structural changes, we did not find any higher focal
brain volume in AD-hallu compared to AD-c, showing that hallucinations are
only correlated to atrophy. However, we also found hypermetabolisms with a
predominant left side of the brain pattern. We suppose that these predominant
left hypermetabolisms are compensatory phenomena, including the left superior
frontal gyrus, the left fusiform, and postcentral gyri.
Only one previous study evaluated 16 visual hallucinations of a patient with a
neurodegenerative disease (Parkinson’s disease) during fMRI scan. This subject
showed significantly less cortical activation in the occipital visual cortex (right
lingual gyrus) and markedly increased activation in the bilateral cingulate and
insula, right medial frontal gyrus, right postcentral gyrus, right thalamus and
brainstem [35]. These regions are coherent with those found in our study.
We have observed differences between the functional PET analysis and the
structural MRI analysis. These differences could be due to the fact that the patients
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with the FDG-PET represent the half of the whole AD-hallu group. But more
probably, these differences are due to the fact that usually in AD the
hypometabolism is more important than the atrophy [43] Another reason could
be du to the fact that a part of the hallucinated patients have also a DLB (see
infra): DLB is reponsible for synaptic dysfunction (functional) more than neuron
destruction (structural) [44].
The results of this study are coherent with the top-down/bottom-up hypotheses
on hallucinations [16] since we have found key region for attention (i.e. the
anterior part of the insula), and also a large part of the right frontal lobe with
respectively structural and functional, and functional involvement, compatible
with impaired attentional binding, and atrophy of the lingual gyri compatible
with perceptual impairment. The results of this study are also compatible with the
hypotheses of Shine et al., since the involvement of the anterior insula as a core
region of hallucinations could be responsible for a conflict resolution processed by
neural network unprepared to do it [19]: default mode network (DMN) and
ventral attention network (VAN) also named salience network. Moreover, recently
Shine et al., have demonstrated that PD patients with hallucinations compared to
PD patients without have the same atrophy found here i.e. clear atrophy of the
anterior part of the insula [38]. The anterior insula is proposed to act in
conjunction with cortical and sub-cortcal hubs within the VAN to activate the
Dorsal Anterior Network (DAN) in the presence of environmental salience.
Patients with atrophy in the anterior insula may have lost the ability to effectively
‘‘switch’’ [45] their attention in the presence of an ambiguous stimulus, leading to
an inability to appropriately activate the DAN [38].
The question of the diagnosis in all studies on cognitive neurodegenerative
diseases is of importance. Here we used the research Dubois’ criteria for the
diagnosis of the patients [23]. These criteria have a known specificity of 93% [22],
that is a very good specificity. Moreover, 62% of the AD patients with
hallucinations have had a CSF analysis and all these patients have CSF results in
favor of AD. However, some of these patients have probably AD and the diagnosis
of DLB. Diagnostic classification of DLB is based on McKeith’s criteria with core
diagnostic features of DLB being (1) recurrent visual hallucinations, (2) cognitive
fluctuations, and (3) spontaneous motor features of parkinsonism [46]. The
presence of one of these core signs is sufficient for a diagnosis of possible DLB,
and two for probable DLB [46]. Interestingly the McKeith’s criteria have an
excellent specificity (more than 95%) [47, 48] when compared to gold standard
neuropathological diagnosis. Against the AD and DLB hypothesis, we have the
poor percentage of parkinsonism in our cohort, but we don’t have any
information in ADNI about fluctuations [46], and the presence of hallucinations
and dementia in our AD-hallu group is sufficient to diagnose a possible DLB.
Previous neuropathological analysis in a subset of the ADNI cohort showed that
among 22 patients with the diagnosis of AD (MCI or dementia), only seven had a
pure AD [30]. The majority of the patients had mixed pathology including AD
and LBD (n56), AD and medial temporal lobe pathology (MTLP: TDP-43
proteinopathy, argyrophilic grain disease and hippocampal sclerosis) (n55), and
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AD and DLB and MTLP (n54). Moreover in this study, hallucinations were a
strong predictor of coincident DLB (specificity5100%). We have checked the
neuropathological status of the patients of our study using the article of Toledo et
al., [30] and we have found that the 4 patients autopsied in the AD-hallu group
have the mixed pathology AD and DLB. So it is highly probable that
hallucinations studied here are secondary not only to AD but AD and DLB, and
that the neural basis of hallucinations here are those of AD and DLB. Interestingly,
anterior part of the insula was recently recognized as a biomarker of DLB. Indeed,
a metanalysis of gray matter atrophy in DLB using VBM was conducted [49].
Seven studies including 218 DLB patients compared to 219 controls showed an
insular cortex atrophy predominantly on the right in DLB patients.
The first limitation of our study is the absence of details on hallucinations
because only the NPI-Q was used. Two types of information were not known: the
type and the occurrence of hallucinations. Thus, it is not known whether the
subjects were actively hallucinating during the FDG-PET scans. It is worth noting
that there may be differences in anatomical and functionnal patterns identified in
imaging studies associated with chronic hallucinations versus the rare occurrence
of capturing acute hallucinations [35]. However, even if there are no clinical data
in the ADNI on the type of hallucinations in patients, it is known that in AD
visual hallucinations are more frequent than auditory verbal hallucinations [16].
Moreover, since hallucinations are less frequent in AD than in other
neurodegenerative diseases, such as DLB, the only way that one can study so many
patients with AD and hallucinations is to have recourse to a cohort as large as the
ADNI. The second limitation is that, among the patients with brain MRI (n539),
only a half had brain FDG-PET. Thus, the "core region" reflect a much smaller
subset of patients, and this could introduce substantial bias. This limitation is
inherent in the ADNI cohort, in which only about half of the patients have FDG-
PET.
In our study, the presence of hallucinations in AD (or AD and DLB) was
correlated with a vast anterior-posterior network, with a predominant right brain
involvement. We suppose that patients have a top-down control failure, and also a
dysfunction of the bottom-up visual processes. Top-down mechanisms are
underlain by the right anterior insula and the right frontal lobe known to be
involved in false attribution of a source to a stimulus and deficient intuitive
judgment. Bottom-up mechanisms are involved in visuo-perceptual processing
with posterior regions. Taken together, all these data are consistent with
previously published data on hallucinations in neurodegenerative diseases.
Further studies are now needed to elucidate more precisely the anatomic and
functional connections underlying hallucinations in AD patients.
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